Lucid reports Q1 results

By staff writers

May 13, 2022 -- Lucid Diagnostics recently disclosed results for the first quarter of the 2022 fiscal year, which ended March 31. The company has begun ramping up sales of its EsoGuard DNA tests.

The company reported its revenue to be $189,000, with a net loss of $12,270. Gross profit, meanwhile, was reported to be $180,000.

Lucid said it processed 533 commercial EsoGuard DNA tests in the quarter, a 76% increase sequentially from the fourth quarter of 2021 and a nearly 500% increase annually from the first quarter of 2021.

Lucid’s LucidDx Labs signs deal with MediNcrease
Pavmed subsidiary Lucid Diagnostics announced that its laboratory LucidDx Labs has signed a deal to supply its EsoGuard DNA test to members of MediNcrease...
Lucid promotes new guideline from ACG on esophageal cancer
Diagnostics developer Lucid Diagnostics is highlighting updated clinical guidelines for esophageal cancer screening from the American College of Gastroenterology...
1st patient enrolled in study for Lucid's EsoGaurd test
Lucid Diagnostics said the first patient has been enrolled in a study of the company's EsoGuard Esophageal DNA Test at the Louis Stokes Cleveland Department...
Lucid launches 3 new test centers
Lucid Diagnostics, a Pavmed subsidiary, has launched Lucid Test Centers in Seattle, Portland, and Boise, ID. After physician referrals, patients can get...
Lucid closes Nasdaq initial public offering
The cancer prevention medical diagnostics firm Lucid Diagnostics, a subsidiary of PAVmed, has closed its initial public offering.

Copyright © 2022

Last Updated 5/13/2022 2:45:54 PM